ELAN Q4 2023 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.0B+4.8% YoY

Gross Profit

$381M36.8% margin

Operating Income

$10M1.0% margin

Net Income

-$141M-13.6% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-3.1%

Cash Flow

Operating Cash Flow

$157M

Free Cash Flow

$116M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$14.4B

Total Liabilities

$8.1B

Stockholders' Equity

$6.2B

Cash & Equivalents

$352M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$988M	+4.8%
Gross Profit	$381M	$410M	-7.1%
Operating Income	$10M	$27M	-63.0%
Net Income	-$141M	-$54M	-161.1%

Revenue Segments

Farm Animal

$610M38%

Pet Health

$416M26%

Cattle

$249M16%

Poultry

$220M14%

Swine

$98M6%

Contract Manufacturing

$9M1%

Geographic Segments

Non-US

$574M55%

UNITED STATES

$461M45%